Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 3,938 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,938 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $6.29, for a total transaction of $24,770.02. Following the completion of the sale, the insider owned 753,562 shares of the company’s stock, valued at approximately $4,739,904.98. This represents a 0.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The stock was sold at an average price of $5.87, for a total value of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total value of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total value of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The shares were sold at an average price of $6.32, for a total value of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total transaction of $28,560.18.

Clene Stock Performance

Shares of CLNN stock opened at $6.28 on Thursday. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The company has a market capitalization of $64.87 million, a price-to-earnings ratio of -1.85 and a beta of 0.87. The company has a 50-day simple moving average of $7.88 and a 200 day simple moving average of $6.39.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. Sell-side analysts forecast that Clene Inc. will post -5.19 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp acquired a new stake in Clene during the third quarter worth about $29,000. Jane Street Group LLC bought a new stake in shares of Clene during the 2nd quarter worth approximately $47,000. Lunt Capital Management Inc. boosted its position in shares of Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after acquiring an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP increased its stake in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the last quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Wall Street Analyst Weigh In

CLNN has been the topic of a number of research reports. Benchmark reaffirmed a “buy” rating on shares of Clene in a report on Thursday, December 4th. D. Boral Capital restated a “buy” rating and issued a $23.00 price target on shares of Clene in a research note on Wednesday, December 10th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Clene presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).